Vise Technologies Inc. Invests $5.62 Million in Pfizer Inc. $PFE

Vise Technologies Inc. bought a new stake in Pfizer Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 231,632 shares of the biopharmaceutical company’s stock, valued at approximately $5,615,000.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Pacer Advisors Inc. increased its position in shares of Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after purchasing an additional 17,957,928 shares during the period. Amundi grew its holdings in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new position in shares of Pfizer in the first quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. boosted its holdings in shares of Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after acquiring an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.18.

Pfizer Price Performance

Pfizer stock opened at $24.45 on Monday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The firm has a market capitalization of $138.99 billion, a P/E ratio of 13.00, a PEG ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business has a fifty day moving average price of $24.74 and a 200-day moving average price of $24.38.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.